ReviewAdvances in therapy2022

Perspectives on Subcutaneous Infliximab for Rheumatic Diseases and Inflammatory Bowel Disease: Before, During, and After the COVID-19 Era.

Stefan Schreiber et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.